UBS Group
TRAX

UBS Group’s First Tracks Biotherapeutics TRAX Stock Holding History

UBS Group’s Portfolio TRAX Stock Details TRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.26M Buy
+310,886
New +$5.81M ﹤0.01% 3928

Other funds holding TRAX

AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

UBS Group's TRAX Position: Q2 2026 in Review

UBS Group opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 310,886 shares worth $6.26M. The stake represents ﹤0.01% of the portfolio and ranks #3928 among its holdings.

89 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

  • UBS Group held 310,886 shares of First Tracks Biotherapeutics worth $6.26M as of Q2 2026.
  • First Tracks Biotherapeutics was a new UBS Group position in Q2 2026.
  • First Tracks Biotherapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3928 holding.
  • 89 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.